Artículo
Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
Fecha de publicación:
08/2017
Editorial:
Informa Healthcare
Revista:
Expert Opinion on Investigational Drugs
ISSN:
1354-3784
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Introduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability. Neuroprotective effects in animal PD models have been shown for the angiotensin-converting enzyme (ACE) inhibitors captopril and perindopril, and the AT1 receptor antagonists losartan, candesartan and telmisartan. These effects appear to be mediated by a reduction in the overproduction of reactive oxygen species. In a proof-of-concept, randomized, double-blind, crossover study in PD patients, perindopril enhanced the effect of levodopa without inducing dyskinesias. There has not been any clinical trial exploring the neuroprotective effect of RAS drugs, but one cohort study in hypertensive patients suggested a protective effect of ACE inhibitors on PD risk. RAS is a promising target for symptomatic and neuroprotective therapies in PD. Further studies in PD animal models and patients are warranted.
Palabras clave:
Parkinson Disease
,
Angiotensin
,
Neuroprotection
,
Renin
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(ININCA)
Articulos de INST.DE INVEST.CARDIOLOGICAS (I)
Articulos de INST.DE INVEST.CARDIOLOGICAS (I)
Citación
Pérez Lloret, Santiago; Otero-Losada, Matilde Estela; Toblli, Jorge Eduardo; Capani, Francisco; Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease; Informa Healthcare; Expert Opinion on Investigational Drugs; 26; 10; 8-2017; 1163-1173
Compartir
Altmétricas